Aehr Test Systems (AEHR) shares skyrocketed on July 15 after the company reported stellar fiscal fourth-quarter results and issued forward guidance that far exceeded analyst expectations. The stock now trades more than four times higher than its price at the start of 2026, prompting some investors to question whether the rally has gone too far.
What Drove the Post-Earnings Surge?
The company's fiscal 2027 revenue forecast of $140 million—nearly triple last year's top line and well above the consensus estimate of $85 million—was the primary catalyst. Management also revealed that the quarter ended with approximately $101 million in backlog, meaning roughly 72% of that ambitious revenue target is already booked. A book-to-bill ratio of 3.2x in Q4 further underscored strong demand.
Equally important, Aehr has successfully diversified away from the sluggish electric vehicle (EV) silicon carbide market. Non-EV segments—including AI accelerators, silicon photonics, and optical transceivers—now account for 95% of recent annual revenue, reducing reliance on a single end market.
Why Some Investors Are Taking Profits
Despite the fundamental improvements, several red flags suggest the current price may not be sustainable. At its present level, AEHR trades at an eye-watering 48x price-to-sales (P/S) multiple—a valuation typically reserved for high-margin software companies, not cyclical hardware manufacturers. The company also remains unprofitable on a trailing twelve-month basis, with negative earnings per share of $0.38.
Insider activity adds to the caution. Over the past three months, there have been 19 sell transactions and zero buys. While many of these sales were tied to tax obligations on vesting shares, the pattern is bearish and could amplify selling pressure in the second half of 2026.
Technical Resistance at $95
From a technical perspective, AEHR challenged its 50-day moving average near $95 but failed to break decisively above that level. This rejection at a key resistance suggests the immediate upside may be capped, and the stock remains vulnerable to profit-taking. The consensus analyst rating is still a "Moderate Buy," but the mean price target of roughly $71 has already been left far behind, indicating that the Street, on average, views the stock as overvalued.
For context, broader market sentiment has been mixed. The Dow climbed 148 points recently on positive inflation data, while BlackRock surged 5% on its Q2 earnings beat, showing that strong earnings can still drive gains in other names. However, Aehr's extreme valuation and insider selling make it a standout risk.
Bottom Line
Aehr Test Systems' business is clearly improving, and its diversification away from EV markets is a positive long-term development. But at 48x sales for an unprofitable hardware company, the risk-reward equation looks unfavorable. Investors may want to use the post-earnings rally as an opportunity to lock in gains and redeploy capital into names with more reasonable valuations.
This article is for informational purposes only and does not constitute financial advice.
